[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Pamidronic acid.]
[J01GA01, streptomycin, Pamidronic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Pamidronic acid may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Pamidronic acid may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Pamidronic acid may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Pamidronic acid.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Pamidronic acid.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Tacrine.]
[N05CD07, temazepam, Pamidronic acid may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, Pamidronic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Pamidronic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Pamidronic acid may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Tetracaine.]
[S03AA02, tetracycline, Pamidronic acid may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftaroline fosamil.]
[L04AX02, thalidomide, The risk or severity of nephrotoxicity can be increased when Thalidomide is combined with Pamidronic acid.]
[P02CA02, thiabendazole, Pamidronic acid may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Pamidronic acid may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[G04BE06, moxisylyte, Pamidronic acid may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL03, tiapride, Pamidronic acid may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Pamidronic acid may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, Pamidronic acid may decrease the excretion rate of Timolol which could result in a higher serum level.]
[P01AB02, tinidazole, Pamidronic acid may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Pamidronic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Pamidronic acid may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Pamidronic acid may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Pamidronic acid.]
[N02AX02, tramadol, Pamidronic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Triazolam.]
[A16AX12, trientine, Pamidronic acid may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Pamidronic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[A03AA05, trimebutine, Pamidronic acid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Trimethoprim.]
[R03DX07, roflumilast, Pamidronic acid may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Pamidronic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Pamidronic acid may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[S01AA28, vancomycin, Pamidronic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Pamidronic acid may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Pamidronic acid may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, Pamidronic acid may decrease the excretion rate of Verapamil which could result in a higher serum level.]
[N06AX09, viloxazine, Pamidronic acid may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Vincristine.]
[B03BA01, vitamin B12, Pamidronic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, Pamidronic acid may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Zidovudine.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Pamidronic acid.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Fusidic acid.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Tiludronic acid.]
[B06AC02, icatibant, Pamidronic acid may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[A02BC04, rabeprazole, Pamidronic acid may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Ibandronate.]
[V03AC02, deferiprone, Pamidronic acid may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Pamidronic acid.]
[L01EJ01, ruxolitinib, Pamidronic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Pamidronic acid may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Pamidronic acid may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[M01CB03, auranofin, Pamidronic acid may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[S01LA05, aflibercept, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Aflibercept is combined with Pamidronic acid.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Pamidronic acid.]
[L01BC07, azacitidine, Pamidronic acid may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Pamidronic acid may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Pamidronic acid may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Pamidronic acid may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Bacitracin.]
[M03BX01, baclofen, Pamidronic acid may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Pamidronic acid may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Pamidronic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Pamidronic acid may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[A02AA05, magnesium silicate, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium silicate.]
[A02AC02, calcium silicate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium silicate.]
[D02BA02, octinoxate, Pamidronic acid may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[N04BD02, rasagiline, Pamidronic acid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Lercanidipine.]
[V09IX04, fluorodeoxyglucose F18, Pamidronic acid may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Pamidronic acid.]
[V08CA11, gadofosveset, Pamidronic acid may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Pamidronic acid may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Pamidronic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Pamidronic acid may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[L04AX06, pomalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Pamidronic acid.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Benorilate is combined with Pamidronic acid.]
[A10BK02, canagliflozin, Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Benzocaine.]
[L03AA12, ancestim, Pamidronic acid may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Pamidronic acid.]
[N04AC01, benztropine, Pamidronic acid may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Pamidronic acid.]
[L01EE01, trametinib, Pamidronic acid may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Pamidronic acid.]
[V09AX05, florbetapir F-18, Pamidronic acid may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX28, levomilnacipran, Pamidronic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A10BJ03, lixisenatide, Pamidronic acid may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Pamidronic acid may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Pamidronic acid may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Pamidronic acid may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP08, sofosbuvir, Pamidronic acid may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[C01CA27, droxidopa, Pamidronic acid may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Pamidronic acid may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Pamidronic acid may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Pamidronic acid may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Betamethasone.]
[V03AB34, fomepizole, Pamidronic acid may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Bezafibrate.]
[V08AA01, diatrizoic acid, Pamidronic acid may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Pamidronic acid may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Pamidronic acid.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, Pamidronic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Pamidronic acid may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N02BE01, acetaminophen, Pamidronic acid may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Pamidronic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Adefovir dipivoxil.]
[A06AD03, magnesium peroxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Pamidronic acid.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Pamidronic acid.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Acipimox.]
[V03AB37, idarucizumab, Pamidronic acid may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, Pamidronic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Pamidronic acid may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[M04AB05, lesinurad, Pamidronic acid may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Pamidronic acid.]
[A02AB06, aloglutamol, The serum concentration of Pamidronic acid can be decreased when it is combined with Aloglutamol.]
[N03AX23, brivaracetam, Pamidronic acid may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Pamidronic acid may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Pamidronic acid can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Pamidronic acid can be decreased when it is combined with Aluminium phosphate.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Levobupivacaine.]
[N05BE01, buspirone, Pamidronic acid may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, Pamidronic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Pamidronic acid may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Pamidronic acid.]
[A06AH05, naldemedine, Pamidronic acid may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Pamidronic acid may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pamidronic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium carbonate.]
[P01CA02, benznidazole, Pamidronic acid may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium chloride.]
[J05AF06, abacavir, Pamidronic acid may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[D11AX03, calcium gluconate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium gluconate.]
[N07XX13, valbenazine, Pamidronic acid may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pamidronic acid.]
[A12AA01, calcium phosphate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium Phosphate.]
[P01AX10, fumagillin, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Pamidronic acid.]
[J01MA23, delafloxacin, Pamidronic acid may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Pamidronic acid may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[A02BX12, bismuth subnitrate, The serum concentration of Pamidronic acid can be decreased when it is combined with Bismuth subnitrate.]
[C07AB07, bisoprolol, Pamidronic acid may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefprozil.]
[R03BA02, budesonide, Pamidronic acid may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Bumadizone is combined with Pamidronic acid.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Capsaicin.]
[R06AX18, acrivastine, Pamidronic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Captopril.]
[L02BB05, apalutamide, Pamidronic acid may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Pamidronic acid may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium polycarbophil.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Carbimazole.]
[L04AA37, baricitinib, Pamidronic acid may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftibuten.]
[J01GB14, plazomicin, Pamidronic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[A16AX14, migalastat, Pamidronic acid may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Pamidronic acid may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, Pamidronic acid may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Pamidronic acid may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Pamidronic acid.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Inotersen.]
[L01AD01, carmustine, Pamidronic acid may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[A06AX05, prucalopride, Pamidronic acid may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AC23, cilostazol, Pamidronic acid may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ciprofibrate.]
[N06BA14, solriamfetol, Pamidronic acid may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Pamidronic acid may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ubidecarenone.]
[V03AE07, calcium acetate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium acetate.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefaclor.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefazolin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Pamidronic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefotaxime.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Pamidronic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftazidime.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefuroxime.]
[N07XX11, pitolisant, Pamidronic acid may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[S01LA06, brolucizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Pamidronic acid.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Pamidronic acid.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefalotin.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefradine.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Givosiran.]
[M09AX08, golodirsen, Pamidronic acid may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Pamidronic acid may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[R02AA03, dichlorobenzyl alcohol, Pamidronic acid may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Pamidronic acid may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Pamidronic acid.]
[C08CA16, clevidipine, Pamidronic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Pamidronic acid.]
[V08CA05, mangafodipir, Pamidronic acid may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Pamidronic acid.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Dyclonine.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Chloroquine.]
[N05AA01, chlorpromazine, Pamidronic acid may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.]
[A10BB02, chlorpropamide, Pamidronic acid may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[M03BB03, chlorzoxazone, Pamidronic acid may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Ethenzamide is combined with Pamidronic acid.]
[N02BA03, choline salicylate, Pamidronic acid may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Pamidronic acid.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Pamidronic acid.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Etofibrate.]
[M01AX25, chondroitin sulfates, Pamidronic acid may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Pamidronic acid.]
[C01CA19, fenoldopam, Pamidronic acid may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DD15, cefdinir, Pamidronic acid may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Pamidronic acid may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[N02BG07, flupirtine, Pamidronic acid may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[S01LA08, bevacizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cimetidine.]
[V08CA04, gadoteridol, Pamidronic acid may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Pamidronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Pamidronic acid may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Pamidronic acid may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Pamidronic acid may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Pamidronic acid.]
[A12AA02, calcium glubionate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium glubionate anhydrous.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Clofibrate.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Levobupivacaine.]
[N06AA04, clomipramine, Pamidronic acid may decrease the excretion rate of Clomipramine which could result in a higher serum level.]
[N03AE01, clonazepam, Pamidronic acid may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, Pamidronic acid may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[N05AH02, clozapine, Pamidronic acid may decrease the excretion rate of Clozapine which could result in a higher serum level.]
[J01GB12, arbekacin, Pamidronic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Cocaine.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Proquazone is combined with Pamidronic acid.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Colchicine.]
[J01XB01, colistin, Pamidronic acid may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefpirome.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Leflunomide.]
[A02AD04, hydrotalcite, The serum concentration of Pamidronic acid can be decreased when it is combined with Hydrotalcite.]
[A04AA03, tropisetron, Pamidronic acid may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Pamidronic acid may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Imidazole salicylate is combined with Pamidronic acid.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Indobufen is combined with Pamidronic acid.]
[J05AB14, valganciclovir, Pamidronic acid may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Pamidronic acid may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Pamidronic acid may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Pamidronic acid may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Pamidronic acid may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Pamidronic acid may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Pamidronic acid.]
[N02CC05, almotriptan, Pamidronic acid may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Pamidronic acid.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Acyclovir.]
[N05BA10, ketazolam, Pamidronic acid may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Pamidronic acid.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pamidronic acid.]
[N03AX09, lamotrigine, Pamidronic acid may decrease the excretion rate of Lamotrigine which could result in a higher serum level.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Nafarelin.]
[N07BC04, lofexidine, Pamidronic acid may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Lonazolac is combined with Pamidronic acid.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Loxoprofen is combined with Pamidronic acid.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Loracarbef.]
[C09AA03, lisinopril, Pamidronic acid may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A02AD02, magaldrate, The serum concentration of Pamidronic acid can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium carbonate.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Mebeverine.]
[J01DH02, meropenem, Pamidronic acid may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[N05AD03, metylperon, Pamidronic acid may decrease the excretion rate of Melperone which could result in a higher serum level.]
[J05AF07, tenofovir disoproxil, Pamidronic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Pamidronic acid.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Mofebutazone is combined with Pamidronic acid.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Pamidronic acid.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Pamidronic acid.]
[L01AX04, dacarbazine, Pamidronic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Pamidronic acid.]
[N07BB05, nalmefene, Pamidronic acid may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Pamidronic acid may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Pamidronic acid may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Pamidronic acid may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Pamidronic acid may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Pamidronic acid may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Pamidronic acid.]
[N06AA01, desipramine, Pamidronic acid may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Pamidronic acid may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[V04CH02, indigo carmine, Pamidronic acid may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Pamidronic acid may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Pamidronic acid.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Dexamethasone.]
[N06BA02, dextroamphetamine, Pamidronic acid may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Pamidronic acid may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Pamidronic acid may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Pamidronic acid may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Cinchocaine.]
[R05DA08, pholcodine, Pamidronic acid may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Pamidronic acid.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Foscarnet.]
[A03AA07, dicyclomine, Pamidronic acid may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Pamidronic acid may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C03CA03, piretanide, The risk or severity of hypocalcemia can be increased when Piretanide is combined with Pamidronic acid.]
[C08CA03, isradipine, Pamidronic acid may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[D07XC04, diflucortolone, Pamidronic acid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Pamidronic acid.]
[C01AA05, digoxin, Pamidronic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Pamidronic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Pamidronic acid.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Atazanavir.]
[H03BC01, potassium perchlorate, Pamidronic acid may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pamidronic acid may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Pramocaine.]
[V03AB09, dimercaprol, Pamidronic acid may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Pamidronic acid may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Propyphenazone is combined with Pamidronic acid.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Proglumetacin is combined with Pamidronic acid.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Diphenhydramine.]
[S01AX06, resorcinol, Pamidronic acid may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Pamidronic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R06AE09, levocetirizine, Pamidronic acid may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Pamidronic acid.]
[G04BE08, tadalafil, Pamidronic acid may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Pamidronic acid.]
[C01EB18, ranolazine, Pamidronic acid may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Pamidronic acid.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Pamidronic acid.]
[C01CA07, dobutamine, Pamidronic acid may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Pamidronic acid may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, Pamidronic acid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01AA02, doxycycline, Pamidronic acid may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[A08AA10, sibutramine, Pamidronic acid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, The serum concentration of Pamidronic acid can be decreased when it is combined with Sodium bicarbonate.]
[A12CA02, sodium sulfate, Pamidronic acid may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Pamidronic acid may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Pamidronic acid may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Pamidronic acid may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[L01AX03, temozolomide, Pamidronic acid may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Pamidronic acid.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Terbinafine.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Pamidronic acid.]
[N06AG03, toloxatone, Pamidronic acid may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Pamidronic acid may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, Pamidronic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03CA04, torsemide, The risk or severity of hypocalcemia can be increased when Torasemide is combined with Pamidronic acid.]
[N05CC01, chloral hydrate, Pamidronic acid may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N06AX16, venlafaxine, Pamidronic acid may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Pamidronic acid.]
[N03AX15, zonisamide, Pamidronic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Carboplatin.]
[C02AC02, guanfacine, Pamidronic acid may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Iloprost.]
[L03AX05, pidotimod, Pamidronic acid may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, Pamidronic acid may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pamidronic acid may decrease the excretion rate of Pantoprazole which could result in a higher serum level.]
[G03CA03, estradiol, Pamidronic acid may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Pamidronic acid may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Pamidronic acid may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Fluvastatin.]
[V08CA03, gadodiamide, Pamidronic acid may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01BD05, ibutilide, Pamidronic acid may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Etidocaine.]
[N01AX07, etomidate, Pamidronic acid may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Tacrolimus.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Nizatidine.]
[P01AX07, trimetrexate, Pamidronic acid may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Pamidronic acid may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Pamidronic acid may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pamidronic acid.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Pamidronic acid.]
[M01CB01, gold sodium thiomalate, Pamidronic acid may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Pamidronic acid may decrease the excretion rate of Dextran which could result in a higher serum level.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Etidronic acid.]
[V03AF02, dexrazoxane, Pamidronic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A16AA01, levocarnitine, Pamidronic acid may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Pamidronic acid.]
[N02AB03, fentanyl, Pamidronic acid may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Pamidronic acid may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, Pamidronic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Pamidronic acid.]
[N07AX03, cevimeline, Pamidronic acid may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Pamidronic acid may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Pamidronic acid.]
[J02AC01, fluconazole, Pamidronic acid may decrease the excretion rate of Fluconazole which could result in a higher serum level.]
[J02AX01, flucytosine, Pamidronic acid may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Pamidronic acid may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ethanol.]
[L01BC09, floxuridine, Pamidronic acid may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[N05CD01, flurazepam, Pamidronic acid may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Pamidronic acid.]
[L02BB01, flutamide, Pamidronic acid may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Pamidronic acid may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Pamidronic acid may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Pamidronic acid.]
[L01BC03, tegafur, Pamidronic acid may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Furosemide.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Alendronic acid.]
[N05CF04, eszopiclone, Pamidronic acid may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Gemfibrozil.]
[J01XA03, telavancin, Pamidronic acid may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[A12AA13, calcium citrate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium citrate.]
[A12AA10, calcium gluceptate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium lactate.]
[A12AA30, calcium levulinate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium levulinate.]
[A10BB07, glipizide, Pamidronic acid may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Pamidronic acid may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[L01EX02, sorafenib, Pamidronic acid may decrease the excretion rate of Sorafenib which could result in a higher serum level.]
[M01CB04, aurothioglucose, Pamidronic acid may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pamidronic acid may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Pamidronic acid may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Pamidronic acid may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Pamidronic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, Pamidronic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AH04, quetiapine, Pamidronic acid may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Pamidronic acid may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Pamidronic acid may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[G03DC01, allylestrenol, Pamidronic acid may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Pamidronic acid.]
[C01CE02, milrinone, Pamidronic acid may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Pamidronic acid.]
[C09AA04, perindopril, Pamidronic acid may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Pamidronic acid may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Hydrochlorothiazide.]
[B05XA17, potassium acetate, Pamidronic acid may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[V03AB33, hydroxocobalamin, Pamidronic acid may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Pamidronic acid may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Pamidronic acid may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Pamidronic acid.]
[B05XA08, sodium acetate, Pamidronic acid may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Pamidronic acid may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, Pamidronic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Paclitaxel.]
[R01AD07, tixocortol, Pamidronic acid may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[L01CE01, topotecan, Pamidronic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Pamidronic acid may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Pamidronic acid.]
[A11HA07, inositol, Pamidronic acid may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Pamidronic acid may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Pamidronic acid may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Articaine.]
[A10BH01, sitagliptin, Pamidronic acid may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[S01LA04, ranibizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Pamidronic acid.]
[N05BA12, alprazolam, Pamidronic acid may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Pamidronic acid may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cerivastatin.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Stavudine.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Isoniazid.]
[J05AX05, inosine pranobex, Pamidronic acid may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Pamidronic acid may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ivermectin.]
[S01AA24, kanamycin, Pamidronic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Pamidronic acid.]
[A02AB01, aluminum hydroxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Aluminum hydroxide.]
[N01AX03, ketamine, Pamidronic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Pamidronic acid may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Pamidronic acid.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Pamidronic acid is combined with Deferasirox.]
[D10AX03, azelaic acid, Pamidronic acid may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Pamidronic acid.]
[C07AG01, labetalol, Pamidronic acid may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, Pamidronic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Pamidronic acid may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Etacrynic acid.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Lidocaine.]
[S01AA21, amikacin, Pamidronic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[A12AA11, calcium pangamate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium pangamate.]
[N05BA06, lorazepam, Pamidronic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Pamidronic acid.]
[B05XA11, magnesium chloride, Pamidronic acid may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium oxide.]
[L01BA05, pralatrexate, Pamidronic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Pamidronic acid.]
[N06AA21, maprotiline, Pamidronic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Pamidronic acid may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Pamidronic acid.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Mefloquine.]
[N06DX01, memantine, Pamidronic acid may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Pamidronic acid may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Mepivacaine.]
[G04BX16, tiopronin, Pamidronic acid may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Pamidronic acid may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AX13, paliperidone, Pamidronic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, Pamidronic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BC02, methadone, Pamidronic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Pamidronic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Lamivudine.]
[H03BB02, methimazole, Pamidronic acid may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Pamidronic acid may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pamidronic acid may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Methotrexate.]
[D05BA02, methoxsalen, Pamidronic acid may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Methyldopa.]
[V04CG05, methylene blue, Pamidronic acid may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[G03EK01, methyltestosterone, Pamidronic acid may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Metoclopramide.]
[C03BA08, metolazone, Pamidronic acid may decrease the excretion rate of Metolazone which could result in a higher serum level.]
[C07AB02, metoprolol, Pamidronic acid may decrease the excretion rate of Metoprolol which could result in a higher serum level.]
[V04CD01, metyrapone, Pamidronic acid may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Pamidronic acid.]
[N05CD08, midazolam, Pamidronic acid may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[J05AH01, zanamivir, Pamidronic acid may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Minocycline.]
[L03AC01, aldesleukin, Pamidronic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Amiodarone.]
[N06AA09, amitriptyline, Pamidronic acid may decrease the excretion rate of Amitriptyline which could result in a higher serum level.]
[A04AA05, palonosetron, Pamidronic acid may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Pamidronic acid may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Pamidronic acid may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Pamidronic acid.]
[L04AA06, mycophenolic acid, Pamidronic acid may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Raltegravir.]
[C07AA12, nadolol, Pamidronic acid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Pamidronic acid may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Pamidronic acid may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Naltrexone.]
[N06BA01, amphetamine, Pamidronic acid may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Pamidronic acid.]
[N06AX21, duloxetine, Pamidronic acid may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Pamidronic acid may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pamidronic acid.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Neomycin.]
[B01AC17, tirofiban, Pamidronic acid may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Amphotericin B.]
[S01AA19, ampicillin, Pamidronic acid may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Pamidronic acid may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Pamidronic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Pamidronic acid may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Valaciclovir.]
[C01CE01, inamrinone, Pamidronic acid may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Niacin.]
[C08CA05, nifedipine, Pamidronic acid may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Niflumic acid is combined with Pamidronic acid.]
[C08CA07, nisoldipine, Pamidronic acid may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Pamidronic acid may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Pamidronic acid may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Pamidronic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Pamidronic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Norfloxacin.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ofloxacin.]
[N02AA02, opium, Pamidronic acid may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, Pamidronic acid may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Zoledronic acid.]
[J01CF04, oxacillin, Pamidronic acid may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05BA04, oxazepam, Pamidronic acid may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Pamidronic acid.]
[J04AB30, capreomycin, Pamidronic acid may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Pamidronic acid.]
[G04BD11, fesoterodine, Pamidronic acid may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Pamidronic acid may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Pamidronic acid may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pamidronic acid may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, Pamidronic acid may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pamidronic acid may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Phenazopyridine.]
[N06AF03, phenelzine, Pamidronic acid may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[V03AB36, phentolamine, Pamidronic acid may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Pamidronic acid.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Pamidronic acid.]
[S01AE05, levofloxacin, Pamidronic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Pamidronic acid may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cidofovir.]
[C07AA03, pindolol, Pamidronic acid may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Atorvastatin.]
[J01CA12, piperacillin, Pamidronic acid may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Saquinavir.]
[N06BX03, piracetam, Pamidronic acid may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Pamidronic acid.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefditoren.]
[A10BG02, rosiglitazone, Pamidronic acid may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Pamidronic acid is combined with Polymyxin B.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ritonavir.]
[A10BH03, saxagliptin, Pamidronic acid may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Pamidronic acid may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Pitavastatin.]
[H02AB07, prednisone, Pamidronic acid may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Prilocaine.]
[M04AB01, probenecid, Pamidronic acid may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, Pamidronic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Fenofibrate.]
[R06AD02, promethazine, Pamidronic acid may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[A03AB05, propantheline, Pamidronic acid may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Propofol.]
[C07AA05, propranolol, Pamidronic acid may decrease the excretion rate of Propranolol which could result in a higher serum level.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Pamidronic acid may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Pamidronic acid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Montelukast.]
[N07XX07, dalfampridine, Pamidronic acid may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Pamidronic acid may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pamidronic acid may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[C01BA01, quinidine, Pamidronic acid may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ranitidine.]
[C02AA02, reserpine, Pamidronic acid may decrease the excretion rate of Reserpine which could result in a higher serum level.]
[J05AP01, ribavirin, Pamidronic acid may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Pamidronic acid.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Pamidronic acid.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Pamidronic acid.]
[N05CA06, secobarbital, Pamidronic acid may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[J01GB08, sisomicin, Pamidronic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Pamidronic acid may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Pamidronic acid may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Pamidronic acid.]
[J01GA01, streptomycin, Pamidronic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Pamidronic acid may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Pamidronic acid may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Pamidronic acid may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Pamidronic acid.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Pamidronic acid.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Tacrine.]
[N05CD07, temazepam, Pamidronic acid may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, Pamidronic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Pamidronic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Pamidronic acid may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Tetracaine.]
[S03AA02, tetracycline, Pamidronic acid may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftaroline fosamil.]
[L04AX02, thalidomide, The risk or severity of nephrotoxicity can be increased when Thalidomide is combined with Pamidronic acid.]
[P02CA02, thiabendazole, Pamidronic acid may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Pamidronic acid may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[G04BE06, moxisylyte, Pamidronic acid may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL03, tiapride, Pamidronic acid may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Pamidronic acid may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, Pamidronic acid may decrease the excretion rate of Timolol which could result in a higher serum level.]
[P01AB02, tinidazole, Pamidronic acid may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Pamidronic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Pamidronic acid may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Pamidronic acid may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Pamidronic acid.]
[N02AX02, tramadol, Pamidronic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Triazolam.]
[A16AX12, trientine, Pamidronic acid may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Pamidronic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[A03AA05, trimebutine, Pamidronic acid may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Trimethoprim.]
[R03DX07, roflumilast, Pamidronic acid may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Pamidronic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Pamidronic acid may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[S01AA28, vancomycin, Pamidronic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Pamidronic acid may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Pamidronic acid may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, Pamidronic acid may decrease the excretion rate of Verapamil which could result in a higher serum level.]
[N06AX09, viloxazine, Pamidronic acid may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Vincristine.]
[B03BA01, vitamin B12, Pamidronic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, Pamidronic acid may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Zidovudine.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Pamidronic acid.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Fusidic acid.]
[V08AA04, iothalamic acid, Pamidronic acid may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Pamidronic acid.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, Pamidronic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Pamidronic acid may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N02BE01, acetaminophen, Pamidronic acid may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Pamidronic acid may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[A06AD03, magnesium peroxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Pamidronic acid.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Pamidronic acid.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Acipimox.]
[V03AB37, idarucizumab, Pamidronic acid may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, Pamidronic acid may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Pamidronic acid may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[M04AB05, lesinurad, Pamidronic acid may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Pamidronic acid.]
[A02AB06, aloglutamol, The serum concentration of Pamidronic acid can be decreased when it is combined with Aloglutamol.]
[N03AX23, brivaracetam, Pamidronic acid may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Pamidronic acid may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Pamidronic acid can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Pamidronic acid can be decreased when it is combined with Aluminium phosphate.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Levobupivacaine.]
[N05BE01, buspirone, Pamidronic acid may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, Pamidronic acid may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Pamidronic acid may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Pamidronic acid.]
[A06AH05, naldemedine, Pamidronic acid may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Pamidronic acid may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pamidronic acid may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium carbonate.]
[P01CA02, benznidazole, Pamidronic acid may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium chloride.]
[J05AF06, abacavir, Pamidronic acid may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[D11AX03, calcium gluconate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium gluconate.]
[N07XX13, valbenazine, Pamidronic acid may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pamidronic acid.]
[A12AA01, calcium phosphate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium Phosphate.]
[P01AX10, fumagillin, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Pamidronic acid.]
[J01MA23, delafloxacin, Pamidronic acid may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Pamidronic acid may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[A02BX12, bismuth subnitrate, The serum concentration of Pamidronic acid can be decreased when it is combined with Bismuth subnitrate.]
[C07AB07, bisoprolol, Pamidronic acid may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefprozil.]
[R03BA02, budesonide, Pamidronic acid may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Bumadizone is combined with Pamidronic acid.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Capsaicin.]
[R06AX18, acrivastine, Pamidronic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Captopril.]
[L02BB05, apalutamide, Pamidronic acid may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Pamidronic acid may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium polycarbophil.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Carbimazole.]
[L04AA37, baricitinib, Pamidronic acid may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftibuten.]
[J01GB14, plazomicin, Pamidronic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[A16AX14, migalastat, Pamidronic acid may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Pamidronic acid may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, Pamidronic acid may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Pamidronic acid may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Pamidronic acid.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Inotersen.]
[L01AD01, carmustine, Pamidronic acid may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[A06AX05, prucalopride, Pamidronic acid may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AC23, cilostazol, Pamidronic acid may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ciprofibrate.]
[N06BA14, solriamfetol, Pamidronic acid may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Pamidronic acid may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ubidecarenone.]
[V03AE07, calcium acetate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium acetate.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefaclor.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefazolin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Pamidronic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefotaxime.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Pamidronic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftazidime.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefuroxime.]
[N07XX11, pitolisant, Pamidronic acid may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[S01LA06, brolucizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Pamidronic acid.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Pamidronic acid.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefalotin.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefradine.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Givosiran.]
[M09AX08, golodirsen, Pamidronic acid may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Pamidronic acid may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[R02AA03, dichlorobenzyl alcohol, Pamidronic acid may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Pamidronic acid may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Pamidronic acid.]
[C08CA16, clevidipine, Pamidronic acid may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Pamidronic acid.]
[V08CA05, mangafodipir, Pamidronic acid may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Pamidronic acid.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Dyclonine.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Chloroquine.]
[N05AA01, chlorpromazine, Pamidronic acid may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.]
[A10BB02, chlorpropamide, Pamidronic acid may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[M03BB03, chlorzoxazone, Pamidronic acid may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Ethenzamide is combined with Pamidronic acid.]
[N02BA03, choline salicylate, Pamidronic acid may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Pamidronic acid.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Pamidronic acid.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Etofibrate.]
[M01AX25, chondroitin sulfates, Pamidronic acid may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Pamidronic acid.]
[C01CA19, fenoldopam, Pamidronic acid may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DD15, cefdinir, Pamidronic acid may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Pamidronic acid may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[N02BG07, flupirtine, Pamidronic acid may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[S01LA08, bevacizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cimetidine.]
[V08CA04, gadoteridol, Pamidronic acid may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Pamidronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Pamidronic acid.]
[A12AA02, calcium glubionate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium glubionate anhydrous.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Clofibrate.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Levobupivacaine.]
[N06AA04, clomipramine, Pamidronic acid may decrease the excretion rate of Clomipramine which could result in a higher serum level.]
[N03AE01, clonazepam, Pamidronic acid may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, Pamidronic acid may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[N05AH02, clozapine, Pamidronic acid may decrease the excretion rate of Clozapine which could result in a higher serum level.]
[J01GB12, arbekacin, Pamidronic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Cocaine.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Proquazone is combined with Pamidronic acid.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Colchicine.]
[J01XB01, colistin, Pamidronic acid may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefpirome.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Leflunomide.]
[A02AD04, hydrotalcite, The serum concentration of Pamidronic acid can be decreased when it is combined with Hydrotalcite.]
[A04AA03, tropisetron, Pamidronic acid may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Pamidronic acid may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Imidazole salicylate is combined with Pamidronic acid.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Indobufen is combined with Pamidronic acid.]
[J05AB14, valganciclovir, Pamidronic acid may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Pamidronic acid may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Pamidronic acid may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Pamidronic acid may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Pamidronic acid may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Pamidronic acid may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Pamidronic acid.]
[N02CC05, almotriptan, Pamidronic acid may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Pamidronic acid.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Acyclovir.]
[N05BA10, ketazolam, Pamidronic acid may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Pamidronic acid.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pamidronic acid.]
[N03AX09, lamotrigine, Pamidronic acid may decrease the excretion rate of Lamotrigine which could result in a higher serum level.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Nafarelin.]
[N07BC04, lofexidine, Pamidronic acid may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Lonazolac is combined with Pamidronic acid.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Loxoprofen is combined with Pamidronic acid.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Loracarbef.]
[C09AA03, lisinopril, Pamidronic acid may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A02AD02, magaldrate, The serum concentration of Pamidronic acid can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium carbonate.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Mebeverine.]
[J01DH02, meropenem, Pamidronic acid may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[N05AD03, metylperon, Pamidronic acid may decrease the excretion rate of Melperone which could result in a higher serum level.]
[J05AF07, tenofovir disoproxil, Pamidronic acid may increase the nephrotoxic activities of Tenofovir disoproxil.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Pamidronic acid.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Mofebutazone is combined with Pamidronic acid.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Pamidronic acid.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Pamidronic acid.]
[L01AX04, dacarbazine, Pamidronic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Pamidronic acid.]
[N07BB05, nalmefene, Pamidronic acid may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Pamidronic acid may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Pamidronic acid may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Pamidronic acid may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Pamidronic acid may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Pamidronic acid may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Pamidronic acid.]
[N06AA01, desipramine, Pamidronic acid may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Pamidronic acid may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[V04CH02, indigo carmine, Pamidronic acid may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Pamidronic acid may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Pamidronic acid.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Dexamethasone.]
[N06BA02, dextroamphetamine, Pamidronic acid may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Pamidronic acid may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Pamidronic acid may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Pamidronic acid may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Cinchocaine.]
[R05DA08, pholcodine, Pamidronic acid may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Pamidronic acid.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Foscarnet.]
[A03AA07, dicyclomine, Pamidronic acid may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Pamidronic acid may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C03CA03, piretanide, The risk or severity of hypocalcemia can be increased when Piretanide is combined with Pamidronic acid.]
[C08CA03, isradipine, Pamidronic acid may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[D07XC04, diflucortolone, Pamidronic acid may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Pamidronic acid.]
[C01AA05, digoxin, Pamidronic acid may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Pamidronic acid may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Pamidronic acid.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Atazanavir.]
[H03BC01, potassium perchlorate, Pamidronic acid may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pamidronic acid may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Pramocaine.]
[V03AB09, dimercaprol, Pamidronic acid may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Pamidronic acid may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Propyphenazone is combined with Pamidronic acid.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Proglumetacin is combined with Pamidronic acid.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Diphenhydramine.]
[S01AX06, resorcinol, Pamidronic acid may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Pamidronic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R06AE09, levocetirizine, Pamidronic acid may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Pamidronic acid.]
[G04BE08, tadalafil, Pamidronic acid may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Pamidronic acid.]
[C01EB18, ranolazine, Pamidronic acid may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Pamidronic acid.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Pamidronic acid.]
[C01CA07, dobutamine, Pamidronic acid may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Pamidronic acid may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, Pamidronic acid may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01AA02, doxycycline, Pamidronic acid may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[A08AA10, sibutramine, Pamidronic acid may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, The serum concentration of Pamidronic acid can be decreased when it is combined with Sodium bicarbonate.]
[A12CA02, sodium sulfate, Pamidronic acid may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Pamidronic acid may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Pamidronic acid may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Pamidronic acid may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[L01AX03, temozolomide, Pamidronic acid may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Pamidronic acid.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Terbinafine.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Pamidronic acid.]
[N06AG03, toloxatone, Pamidronic acid may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Pamidronic acid may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, Pamidronic acid may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03CA04, torsemide, The risk or severity of hypocalcemia can be increased when Torasemide is combined with Pamidronic acid.]
[N05CC01, chloral hydrate, Pamidronic acid may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N06AX16, venlafaxine, Pamidronic acid may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Pamidronic acid.]
[N03AX15, zonisamide, Pamidronic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Carboplatin.]
[C02AC02, guanfacine, Pamidronic acid may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Iloprost.]
[L03AX05, pidotimod, Pamidronic acid may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, Pamidronic acid may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pamidronic acid may decrease the excretion rate of Pantoprazole which could result in a higher serum level.]
[G03CA03, estradiol, Pamidronic acid may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Pamidronic acid may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Pamidronic acid may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Fluvastatin.]
[V08CA03, gadodiamide, Pamidronic acid may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01BD05, ibutilide, Pamidronic acid may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Etidocaine.]
[N01AX07, etomidate, Pamidronic acid may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Tacrolimus.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Nizatidine.]
[P01AX07, trimetrexate, Pamidronic acid may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Pamidronic acid may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Pamidronic acid may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pamidronic acid.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Pamidronic acid.]
[M01CB01, gold sodium thiomalate, Pamidronic acid may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Pamidronic acid may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Pamidronic acid may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A16AA01, levocarnitine, Pamidronic acid may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Pamidronic acid.]
[N02AB03, fentanyl, Pamidronic acid may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Pamidronic acid may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, Pamidronic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Pamidronic acid.]
[N07AX03, cevimeline, Pamidronic acid may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Pamidronic acid may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Pamidronic acid.]
[J02AC01, fluconazole, Pamidronic acid may decrease the excretion rate of Fluconazole which could result in a higher serum level.]
[J02AX01, flucytosine, Pamidronic acid may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Pamidronic acid may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ethanol.]
[L01BC09, floxuridine, Pamidronic acid may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[N05CD01, flurazepam, Pamidronic acid may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Pamidronic acid.]
[L02BB01, flutamide, Pamidronic acid may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Pamidronic acid may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Pamidronic acid may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Pamidronic acid.]
[L01BC03, tegafur, Pamidronic acid may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Furosemide.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Alendronic acid.]
[N05CF04, eszopiclone, Pamidronic acid may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Gemfibrozil.]
[J01XA03, telavancin, Pamidronic acid may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[A12AA13, calcium citrate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium citrate.]
[A12AA10, calcium gluceptate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium lactate.]
[A12AA30, calcium levulinate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium levulinate.]
[A10BB07, glipizide, Pamidronic acid may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Pamidronic acid may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[L01EX02, sorafenib, Pamidronic acid may decrease the excretion rate of Sorafenib which could result in a higher serum level.]
[M01CB04, aurothioglucose, Pamidronic acid may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pamidronic acid may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Pamidronic acid may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Pamidronic acid may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Pamidronic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, Pamidronic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AH04, quetiapine, Pamidronic acid may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Pamidronic acid may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Pamidronic acid may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[G03DC01, allylestrenol, Pamidronic acid may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Pamidronic acid.]
[C01CE02, milrinone, Pamidronic acid may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Pamidronic acid.]
[C09AA04, perindopril, Pamidronic acid may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Pamidronic acid may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Hydrochlorothiazide.]
[B05XA17, potassium acetate, Pamidronic acid may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[V03AB33, hydroxocobalamin, Pamidronic acid may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Pamidronic acid may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Pamidronic acid may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Pamidronic acid.]
[B05XA08, sodium acetate, Pamidronic acid may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Pamidronic acid may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, Pamidronic acid may decrease the excretion rate of Imipramine which could result in a higher serum level.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Paclitaxel.]
[R01AD07, tixocortol, Pamidronic acid may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[L01CE01, topotecan, Pamidronic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Pamidronic acid may decrease the excretion rate of Indapamide which could result in a higher serum level.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Pamidronic acid.]
[A11HA07, inositol, Pamidronic acid may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Pamidronic acid may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Pamidronic acid may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Articaine.]
[A10BH01, sitagliptin, Pamidronic acid may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[S01LA04, ranibizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Pamidronic acid.]
[N05BA12, alprazolam, Pamidronic acid may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Pamidronic acid may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cerivastatin.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Stavudine.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Isoniazid.]
[J05AX05, inosine pranobex, Pamidronic acid may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Pamidronic acid may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ivermectin.]
[S01AA24, kanamycin, Pamidronic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Pamidronic acid.]
[A02AB01, aluminum hydroxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Aluminum hydroxide.]
[N01AX03, ketamine, Pamidronic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Pamidronic acid may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Pamidronic acid.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Pamidronic acid is combined with Deferasirox.]
[D10AX03, azelaic acid, Pamidronic acid may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Pamidronic acid.]
[C07AG01, labetalol, Pamidronic acid may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, Pamidronic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Pamidronic acid may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Etacrynic acid.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Lidocaine.]
[S01AA21, amikacin, Pamidronic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[A12AA11, calcium pangamate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium pangamate.]
[N05BA06, lorazepam, Pamidronic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Pamidronic acid.]
[B05XA11, magnesium chloride, Pamidronic acid may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium oxide.]
[L01BA05, pralatrexate, Pamidronic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Pamidronic acid.]
[N06AA21, maprotiline, Pamidronic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Pamidronic acid may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Pamidronic acid.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Mefloquine.]
[N06DX01, memantine, Pamidronic acid may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Pamidronic acid may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Mepivacaine.]
[G04BX16, tiopronin, Pamidronic acid may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Pamidronic acid may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AX13, paliperidone, Pamidronic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, Pamidronic acid may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BC02, methadone, Pamidronic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Pamidronic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Lamivudine.]
[H03BB02, methimazole, Pamidronic acid may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Pamidronic acid may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pamidronic acid may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Methotrexate.]
[D05BA02, methoxsalen, Pamidronic acid may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Methyldopa.]
[V04CG05, methylene blue, Pamidronic acid may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[G03EK01, methyltestosterone, Pamidronic acid may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Metoclopramide.]
[C03BA08, metolazone, Pamidronic acid may decrease the excretion rate of Metolazone which could result in a higher serum level.]
[C07AB02, metoprolol, Pamidronic acid may decrease the excretion rate of Metoprolol which could result in a higher serum level.]
[V04CD01, metyrapone, Pamidronic acid may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Pamidronic acid.]
[N05CD08, midazolam, Pamidronic acid may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[J05AH01, zanamivir, Pamidronic acid may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Minocycline.]
[L03AC01, aldesleukin, Pamidronic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Amiodarone.]
[N06AA09, amitriptyline, Pamidronic acid may decrease the excretion rate of Amitriptyline which could result in a higher serum level.]
[A04AA05, palonosetron, Pamidronic acid may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Pamidronic acid may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Pamidronic acid may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Pamidronic acid.]
[L04AA06, mycophenolic acid, Pamidronic acid may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Raltegravir.]
[C07AA12, nadolol, Pamidronic acid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Pamidronic acid may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Pamidronic acid may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Naltrexone.]
[N06BA01, amphetamine, Pamidronic acid may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Pamidronic acid.]
[N06AX21, duloxetine, Pamidronic acid may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Pamidronic acid may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pamidronic acid.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Neomycin.]
[B01AC17, tirofiban, Pamidronic acid may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Amphotericin B.]
[S01AA19, ampicillin, Pamidronic acid may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Pamidronic acid may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Pamidronic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Pamidronic acid may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Valaciclovir.]
[C01CE01, inamrinone, Pamidronic acid may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Niacin.]
[C08CA05, nifedipine, Pamidronic acid may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Niflumic acid is combined with Pamidronic acid.]
[C08CA07, nisoldipine, Pamidronic acid may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Pamidronic acid may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Pamidronic acid may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Pamidronic acid may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Pamidronic acid may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Norfloxacin.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ofloxacin.]
[N02AA02, opium, Pamidronic acid may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, Pamidronic acid may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Zoledronic acid.]
[J01CF04, oxacillin, Pamidronic acid may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05BA04, oxazepam, Pamidronic acid may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Pamidronic acid.]
[J04AB30, capreomycin, Pamidronic acid may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Pamidronic acid.]
[G04BD11, fesoterodine, Pamidronic acid may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Pamidronic acid may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Pamidronic acid may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pamidronic acid may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, Pamidronic acid may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pamidronic acid may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Phenazopyridine.]
[N06AF03, phenelzine, Pamidronic acid may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[V03AB36, phentolamine, Pamidronic acid may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Pamidronic acid.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Pamidronic acid.]
[S01AE05, levofloxacin, Pamidronic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Pamidronic acid may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cidofovir.]
[C07AA03, pindolol, Pamidronic acid may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Atorvastatin.]
[J01CA12, piperacillin, Pamidronic acid may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Saquinavir.]
[N06BX03, piracetam, Pamidronic acid may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Pamidronic acid.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Cefditoren.]
[A10BG02, rosiglitazone, Pamidronic acid may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Pamidronic acid is combined with Polymyxin B.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ritonavir.]
[A10BH03, saxagliptin, Pamidronic acid may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Pamidronic acid may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Pitavastatin.]
[H02AB07, prednisone, Pamidronic acid may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Prilocaine.]
[M04AB01, probenecid, Pamidronic acid may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, Pamidronic acid may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Fenofibrate.]
[R06AD02, promethazine, Pamidronic acid may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[A03AB05, propantheline, Pamidronic acid may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Propofol.]
[C07AA05, propranolol, Pamidronic acid may decrease the excretion rate of Propranolol which could result in a higher serum level.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Pamidronic acid may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Pamidronic acid may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Montelukast.]
[N07XX07, dalfampridine, Pamidronic acid may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Pamidronic acid may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pamidronic acid may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[C01BA01, quinidine, Pamidronic acid may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Ranitidine.]
[C02AA02, reserpine, Pamidronic acid may decrease the excretion rate of Reserpine which could result in a higher serum level.]
[J05AP01, ribavirin, Pamidronic acid may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Pamidronic acid.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Pamidronic acid.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Pamidronic acid.]
[N05CA06, secobarbital, Pamidronic acid may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[J01GB08, sisomicin, Pamidronic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Pamidronic acid may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Pamidronic acid may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Tiludronic acid.]
[B06AC02, icatibant, Pamidronic acid may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[A02BC04, rabeprazole, Pamidronic acid may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Ibandronate.]
[V03AC02, deferiprone, Pamidronic acid may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Pamidronic acid.]
[L01EJ01, ruxolitinib, Pamidronic acid may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Pamidronic acid may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Pamidronic acid may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[M01CB03, auranofin, Pamidronic acid may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[S01LA05, aflibercept, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Aflibercept is combined with Pamidronic acid.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Pamidronic acid.]
[L01BC07, azacitidine, Pamidronic acid may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Pamidronic acid may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Pamidronic acid may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Pamidronic acid may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Bacitracin.]
[M03BX01, baclofen, Pamidronic acid may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Pamidronic acid may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Pamidronic acid may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Pamidronic acid may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[A02AA05, magnesium silicate, The serum concentration of Pamidronic acid can be decreased when it is combined with Magnesium silicate.]
[A02AC02, calcium silicate, The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium silicate.]
[D02BA02, octinoxate, Pamidronic acid may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[N04BD02, rasagiline, Pamidronic acid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Lercanidipine.]
[V09IX04, fluorodeoxyglucose F18, Pamidronic acid may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Pamidronic acid.]
[V08CA11, gadofosveset, Pamidronic acid may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Pamidronic acid may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Pamidronic acid may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Pamidronic acid may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[L04AX06, pomalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Pamidronic acid.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Benorilate is combined with Pamidronic acid.]
[A10BK02, canagliflozin, Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Benzocaine.]
[L03AA12, ancestim, Pamidronic acid may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Pamidronic acid.]
[N04AC01, benztropine, Pamidronic acid may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Pamidronic acid.]
[L01EE01, trametinib, Pamidronic acid may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Pamidronic acid.]
[V09AX05, florbetapir F-18, Pamidronic acid may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX28, levomilnacipran, Pamidronic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A10BJ03, lixisenatide, Pamidronic acid may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Pamidronic acid may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Pamidronic acid may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Pamidronic acid may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP08, sofosbuvir, Pamidronic acid may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[C01CA27, droxidopa, Pamidronic acid may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Pamidronic acid may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Pamidronic acid may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Pamidronic acid may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Betamethasone.]
[V03AB34, fomepizole, Pamidronic acid may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Bezafibrate.]
[V08AA01, diatrizoic acid, Pamidronic acid may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Adefovir dipivoxil.]
[V09AB03, ioflupane I-123, Pamidronic acid may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Pamidronic acid may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Pamidronic acid may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Etidronic acid.]
